UA116665C2 - Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15) - Google Patents

Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)

Info

Publication number
UA116665C2
UA116665C2 UAA201601817A UAA201601817A UA116665C2 UA 116665 C2 UA116665 C2 UA 116665C2 UA A201601817 A UAA201601817 A UA A201601817A UA A201601817 A UAA201601817 A UA A201601817A UA 116665 C2 UA116665 C2 UA 116665C2
Authority
UA
Ukraine
Prior art keywords
gdf
constructs
differentiation factor
growth differentiation
domain
Prior art date
Application number
UAA201601817A
Other languages
English (en)
Inventor
Юймей Сюн
Ї Чжан
Джекі Ц. Шен
Агнес Ева Хамбургер
Мюріель Веніант-Еллісон
Грант Сімамото
Сяошань Мінь
Чжулунь Ван
Цзє Тан
Гунасекаран Каннан
Марісса Мок
Кеннет Уолкер
Original Assignee
Емджен Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA116665(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Емджен Інк. filed Critical Емджен Інк.
Publication of UA116665C2 publication Critical patent/UA116665C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Винахід стосується гібридного білка, що містить область фактора диференціації і росту 15 (GDF-15), що з'єднана за допомогою поліпептидного лінкеру з Fc-доменом або Fc-доменом, що включає мутацію тирозину до цистеїну в позиції 113. Винахід також стосується димеру та тетраметру гібридного білка та їх застосування в терапії, зокрема для лікування метаболічного порушення, такого як діабет, ожиріння, дисліпідемії або діабетичної нефропатії.
UAA201601817A 2013-07-31 2014-07-31 Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15) UA116665C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361860723P 2013-07-31 2013-07-31
PCT/US2014/049254 WO2015017710A1 (en) 2013-07-31 2014-07-31 Growth differentiation factor 15 (gdf-15) constructs

Publications (1)

Publication Number Publication Date
UA116665C2 true UA116665C2 (uk) 2018-04-25

Family

ID=51358091

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201601817A UA116665C2 (uk) 2013-07-31 2014-07-31 Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)

Country Status (35)

Country Link
US (3) US9862752B2 (uk)
EP (2) EP3763734A1 (uk)
JP (4) JP6509852B2 (uk)
KR (3) KR102376451B1 (uk)
CN (2) CN105980400B (uk)
AP (1) AP2016009011A0 (uk)
AR (1) AR097181A1 (uk)
AU (1) AU2014296107B2 (uk)
BR (1) BR112016002213A2 (uk)
CA (1) CA2918624C (uk)
CL (1) CL2016000249A1 (uk)
CR (1) CR20160097A (uk)
CY (1) CY1123836T1 (uk)
DK (1) DK3027642T3 (uk)
EA (2) EA202092386A1 (uk)
ES (1) ES2828670T3 (uk)
HK (1) HK1225738A1 (uk)
HU (1) HUE050630T2 (uk)
IL (1) IL243749B (uk)
JO (1) JO3566B1 (uk)
LT (1) LT3027642T (uk)
MA (1) MA38873B1 (uk)
MX (2) MX369152B (uk)
NZ (2) NZ754961A (uk)
PE (1) PE20160189A1 (uk)
PH (1) PH12016500208A1 (uk)
PL (1) PL3027642T3 (uk)
PT (1) PT3027642T (uk)
SG (1) SG11201600713RA (uk)
SI (1) SI3027642T1 (uk)
TN (1) TN2016000035A1 (uk)
TW (1) TWI648401B (uk)
UA (1) UA116665C2 (uk)
UY (1) UY35686A (uk)
WO (1) WO2015017710A1 (uk)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5977814B2 (ja) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
EP2807266B1 (en) * 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2918624C (en) * 2013-07-31 2024-02-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
JP2015182969A (ja) * 2014-03-21 2015-10-22 四国化成工業株式会社 トリアゾールシラン化合物、該化合物の合成方法及びその利用
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015198199A1 (en) * 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
CA2952293A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
EP3174894B1 (en) 2014-07-30 2021-06-23 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
NZ730054A (en) 2014-10-31 2023-11-24 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
CN109715206B (zh) 2016-03-31 2023-11-07 恩格姆生物制药公司 结合蛋白及其使用方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) * 2017-08-21 2019-08-13 서울대학교병원 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
KR20200140878A (ko) 2018-04-09 2020-12-16 암젠 인크 성장 분화 인자 15 융합 단백질
TW202019518A (zh) * 2018-07-13 2020-06-01 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體之變體及其用途
JOP20210084A1 (ar) * 2018-10-22 2023-01-30 Janssen Pharmaceutica Nv البروتينات الاندماجية المتمثلة في الببتيد 1 الشبيه بالجلوكاجون (glp1) وعامل تمايز النمو 15 (gdf15) واستخدامها
CA3136969A1 (en) * 2019-04-23 2020-10-29 Lg Chem, Ltd. Fusion polypeptide comprising fc region of immunoglobulin and gdf15
MX2021015045A (es) 2019-06-07 2022-03-17 Amgen Inc Construcciones de unión biespecíficas.
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
AU2020394255A1 (en) * 2019-11-26 2022-06-09 Yuhan Corporation Long-acting GDF15 fusion protein and pharmaceutical composition comprising same
BR112022011540A2 (pt) * 2019-12-11 2022-09-06 Lg Chemical Ltd Polipeptídeo de fusão compreendendo gdf15, composição farmacêutica que compreende o mesmo, dímero e método de preparação do dito polipeptídeo, método para aumentar a estabilidade in vivo de gdf15, molécula de ácido nucleico, vetor e célula recombinantes e uso terapêutico do dito polipeptídeo e dímero
PE20230036A1 (es) 2019-12-23 2023-01-10 Denali Therapeutics Inc Variantes de progranulina
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN115244076B (zh) 2020-10-27 2023-08-04 北京质肽生物医药科技有限公司 Gdf15融合蛋白及其用途
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
CN115925982A (zh) * 2021-08-24 2023-04-07 广东东阳光药业有限公司 Gdf15融合蛋白及其用途
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN115028726B (zh) * 2022-03-31 2024-01-09 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
AU8591198A (en) * 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
AU778939B2 (en) * 1999-01-07 2004-12-23 Emd Lexigen Research Center Corp. Expression and export of anti-obesity proteins as Fc fusion proteins
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
PL209550B1 (pl) 2000-12-07 2011-09-30 Lilly Co Eli Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulinoniezależną i kompozycja do leczenia pacjentów z otyłością
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
EP1395605B8 (en) 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors
JP4422949B2 (ja) 2001-06-26 2010-03-03 武田薬品工業株式会社 ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7737260B2 (en) * 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7101852B2 (en) 2003-05-30 2006-09-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment and prevention of restenosis
AU2004245025A1 (en) * 2003-06-02 2004-12-16 Wyeth Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2005113585A2 (en) * 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
WO2006020884A2 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
KR20080082629A (ko) * 2005-11-10 2008-09-11 리셉터 바이오로직스 인크 간세포 성장인자 인트론 융합 단백질
CN1974601A (zh) * 2005-11-28 2007-06-06 上海新生源医药研究有限公司 一种新型Fc融合蛋白及其生产方法
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
EP2783698A1 (en) 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
ES2774337T3 (es) 2008-01-07 2020-07-20 Amgen Inc Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
JP2011523051A (ja) 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
US8338569B2 (en) 2008-08-04 2012-12-25 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
JP5444363B2 (ja) * 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
US8362210B2 (en) * 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
EP2593428B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
CN108387744A (zh) 2010-08-26 2018-08-10 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
AU2011325833C1 (en) * 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US20140112926A1 (en) 2011-03-16 2014-04-24 Amgen Inc. Fc VARIANTS
JP5977814B2 (ja) * 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を治療または改善する方法
ES2608835T3 (es) * 2011-04-13 2017-04-17 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9527927B2 (en) * 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
EA035344B1 (ru) * 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
AR094271A1 (es) 2012-12-21 2015-07-22 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15
WO2014120619A2 (en) * 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
CA2918624C (en) 2013-07-31 2024-02-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6675333B2 (ja) 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
WO2015198199A1 (en) * 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
CA2952293A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CN109414471A (zh) 2016-05-24 2019-03-01 诺和诺德股份有限公司 Mic-1化合物及其用途
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法

Also Published As

Publication number Publication date
SG11201600713RA (en) 2016-02-26
MX2016001164A (es) 2016-07-26
CR20160097A (es) 2016-07-29
EP3027642B1 (en) 2020-08-19
CL2016000249A1 (es) 2016-07-22
PH12016500208B1 (en) 2016-04-25
CA2918624C (en) 2024-02-13
EP3763734A1 (en) 2021-01-13
EA037355B1 (ru) 2021-03-17
ES2828670T3 (es) 2021-05-27
AU2014296107A1 (en) 2016-02-04
HUE050630T2 (hu) 2020-12-28
US20180079790A1 (en) 2018-03-22
DK3027642T3 (da) 2020-11-02
KR20240000642A (ko) 2024-01-02
PL3027642T3 (pl) 2021-01-11
MX2019012848A (es) 2019-11-28
CN105980400A (zh) 2016-09-28
TN2016000035A1 (en) 2017-07-05
TWI648401B (zh) 2019-01-21
KR20160038896A (ko) 2016-04-07
UY35686A (es) 2015-01-30
HK1225738A1 (zh) 2017-09-15
PE20160189A1 (es) 2016-05-06
AR097181A1 (es) 2016-02-24
MA38873A1 (fr) 2017-09-29
JP2021113219A (ja) 2021-08-05
JP2019178132A (ja) 2019-10-17
IL243749B (en) 2018-06-28
US10894814B2 (en) 2021-01-19
CY1123836T1 (el) 2022-03-24
AP2016009011A0 (en) 2016-01-31
CA2918624A1 (en) 2015-02-05
AU2014296107B2 (en) 2018-07-26
US20210079051A1 (en) 2021-03-18
EA202092386A1 (ru) 2021-04-30
MA38873B1 (fr) 2018-11-30
BR112016002213A2 (pt) 2017-08-29
NZ754961A (en) 2022-04-29
JO3566B1 (ar) 2020-07-05
KR20220038829A (ko) 2022-03-29
LT3027642T (lt) 2020-10-12
CN105980400B (zh) 2021-05-07
MX369152B (es) 2019-10-30
WO2015017710A1 (en) 2015-02-05
JP6509852B2 (ja) 2019-05-08
US20160168213A1 (en) 2016-06-16
JP2023116723A (ja) 2023-08-22
SI3027642T1 (sl) 2020-11-30
KR102616674B1 (ko) 2023-12-29
US9862752B2 (en) 2018-01-09
NZ717030A (en) 2022-04-29
CN113527512A (zh) 2021-10-22
EA201690297A1 (ru) 2016-06-30
KR102376451B1 (ko) 2022-03-23
JP2016532690A (ja) 2016-10-20
PT3027642T (pt) 2020-10-30
PH12016500208A1 (en) 2016-04-25
TW201602345A (zh) 2016-01-16
EP3027642A1 (en) 2016-06-08
JP6877478B2 (ja) 2021-05-26
IL243749A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
UA116665C2 (uk) Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
EA201492053A1 (ru) Белки фактора роста фибробластов 21
JP2016532690A5 (uk)
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201491413A1 (ru) Полипептиды фактора роста и дифференцировки 15 (gdf-15)
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
EA201792199A1 (ru) Слитые белки
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201491550A1 (ru) Применение связывающего белка нейротрофинового рецептора p75ntr в терапевтических целях
EA201401065A1 (ru) Ang2-связывающие молекулы
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
EA201400993A1 (ru) Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения
EA201490697A1 (ru) Белки с двойной функцией для лечения метаболических расстройств
BR112014006535A2 (pt) regulação dos canais de sódio através das proteínas plunc
EA201591839A1 (ru) Терапевтические пептиды
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
PE20130199A1 (es) Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores
EA201590136A1 (ru) Искусственные консенсусные альбумин-связывающие домены
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition